Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Published Date: 18 Feb 2023

Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy

2.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.

3.

Is Vitamin D a Key to Better Breast Cancer Survival?

4.

Immunotherapy after surgery is good for patients with advanced cancer

5.

As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot